Rogocekib
Rogocekib is an orally effective CLK 2 inhibitor, with an IC50 of 1.4 nM, showing anti-tumor activity[1][2].
Product Specifications
CAS Number
[2144751-78-8]
Product Name Alternative
CTX-712
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ctx-712.html
Purity
98.60
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
CC1=NC2=NC=C(C3=C4C(OC)=NC=NN4C=C3)C=C2N1CC5=NN=C([C@H](F)C)O5
Molecular Formula
C19H17FN8O2
Molecular Weight
408.39
References & Citations
[1]Akinori Yoda, et al. CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation. Blood. (2021) 205–206 |[2]Zhen Qin, et al. Development of Cdc2-like Kinase 2 Inhibitors: Achievements and Future Directions. J Med Chem. 2021 Sep 23;64 (18) :13191-13211.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CLK
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
